The CCK-2 receptor agonist Lu-177-PP-F11N for PRRT of medullary thyroid cancer – Recent results of the phase 1 “LUMED” Study
2021
Keywords:
-
Correction
-
Source
-
Cite
-
Save
0
References
0
Citations
NaN
KQI